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A newMcc-knockout mouse model shows impairment of DNA
repair pathways in drug-induced inflammatory lesions leading
to cancer development. The lesions show a strong interferon-g
response regardless of Mcc expression, including novel Irg
genes not previously described in the mouse colon.
BACKGROUND & AIMS: The early events by which inflamma-
tion promotes cancer are still not fully defined. The MCC gene is
silenced by promoter methylation in colitis-associated and
sporadic colon tumors, but its functional significance in pre-
cancerous lesions or polyps is not known. Here, we aimed to
determine the impact of Mcc deletion on the cellular pathways
and carcinogenesis associated with inflammation in the mouse
proximal colon.
METHODS: We generated knockout mice with deletion of Mcc
in the colonic/intestinal epithelial cells (MccDIEC) or in thewhole body (MccD/D). Drug-induced lesions were analyzed by
transcriptome profiling (at 10 weeks) and histopathology (at
20 weeks). Cell-cycle phases and DNA damage proteins were
analyzed by flow cytometry and Western blot of hydrogen
peroxide–treated mouse embryo fibroblasts.
RESULTS: Transcriptome profiling of the lesions showed a
strong response to colon barrier destruction, such as up-
regulation of key inflammation and cancer-associated genes
as well as 28 interferon g–induced guanosine triphosphatase
genes, including the homologs of Crohn’s disease susceptibility
gene IRGM. These features were shared by both Mcc-expressing
and Mcc-deficient mice and many of the altered gene expres-
sion pathways were similar to the mesenchymal colorectal
cancer subtype known as consensus molecular subtype 4
(CMS4). However, Mcc deletion was required for increased
carcinogenesis in the lesions, with adenocarcinoma in 59% of
MccDIEC compared with 19% ofMcc-expressing mice (P ¼ .002).
This was not accompanied by hyperactivation of b-catenin, but
Mcc deletion caused down-regulation of DNA repair genes and
a disruption of DNA damage signaling.
820 Currey et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 4CONCLUSIONS: Loss of Mcc may promote cancer through a
failure to repair inflammation-induced DNA damage. We
provide a comprehensive transcriptome data set of early colo-
rectal lesions and evidence for the in vivo significance of MCC
silencing in colorectal cancer. (Cell Mol Gastroenterol Hepatol
2019;7:819–839; https://doi.org/10.1016/j.jcmgh.2019.01.009)
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https://doi.org/10.1016/j.jcmgh.2019.01.009Tmoter of colorectal cancer is under intense investi-
gation, both in colitis-associated cancer (CAC) and in
sporadic tumors. There are several mouse models that have
shown valuable novel insights into the etiology of CAC, but
the molecular mechanisms and early events by which
inflammation promotes cancer still are poorly understood.1
The MCC gene was discovered as a result of its prox-
imity to APC on chromosome 5,2 but its possible signifi-
cance in carcinogenesis was overlooked until recently.3–9
In colorectal cancers, a common alteration is promoter
methylation that causes MCC silencing,3,4,10 most
frequently in cancers of the proximal colon (58%).11 The
MCC defect appears early in premalignant tumors or le-
sions and is strongly associated with sessile serrated
polyps (80%–86%).4,12,13 Mcc mutations were identified
as drivers of colon or liver carcinogenesis in transposon-
based genetic screens in mice,14,15 but it has not been
reported whether mutated in colorectal cancer (MCC)
deficiency predisposes to cancer in premalignant colon
tumors or lesions.
To further determine the role of MCC in carcinogenesis
in vivo, we generated new knockout mouse models for Mcc.
We focused on the mouse colon and hypothesized that loss
of MCC would have an impact on inflammation-associated
carcinogenesis in the proximal colon. Therefore, we exploi-
ted the drug sulindac, which acts as an irritant in a short
region of the mouse proximal colon.16–18 This highly local-
ized side effect of sulindac is independent of its chemo-
preventive activity in experimental models of colon
cancer.16,19–21 Initially, exposure to sulindac causes micro-
scopic foci of surface tissue erosion. With long-term
administration of the drug (10–20 wk), the foci develop
into visible ulcerated lesions with chronic inflammation that
are surrounded by normal tissue. Most of these lesions are
benign but can develop into adenocarcinoma in strains of
knockout mice with tumor-suppressor gene defects, such as
Apc, p53, Msh2, and Mlh1.16,19,21,22 Here, we show that Mcc
deficiency promotes carcinogenesis in this model through
failure to repair inflammation-induced DNA damage.
Results
Generation of MccF/F, MccDIEC, and MccD/D Mice
A new Mcc-loxP (MccF/F) mouse line was developed
using a gene-targeting approach (Figure 1A) and designated
B6.Cg-Mcc<tm1Maija>/Ausb (MccF/F). We generated both
whole-body knockout (MccD/D) and conditional knockout
mice Vilcre-MccF/F, with loss of Mcc expression in the colonicand intestinal epithelial cells (MccDIEC). The Villin-cre
transgene expresses cre constitutively in the epithelial cells
of the entire crypt-villus axis along the small and large in-
testine, but we focused on the effect of Mcc deletion in the
colon.23 Mcc expression was reduced significantly in the
mucosal layer throughout the colon in the homozygous
MccDIEC mice (Figure 1B). Histopathology of major organs
showed no gross abnormalities or tumors in the whole-
body knockout MccD/D mice, and there was no reduced
survival after a 12-month follow-up period. However, his-
topathology analysis of bromodeoxyuridine (BrdU) incor-
poration in vivo showed that there was a 10%–20%
decrease in the proliferation rate of colon epithelial cells in
MccD/D mice compared with their wild-type (WT) siblings
(Figure 1C).Mcc Deficiency Drives Inflammation-Associated
Cancer
MccDIEC, MccDIEC/WT, and their genotype controls (MccF/F
and MccF/WT) were given feed containing sulindac or control
feed for 20 weeks. As expected, sulindac exposure caused
the development of macroscopic lesions in the mucosal
folds of the proximal colon. Both Mcc-expressing and Mcc-
deficient mice developed these drug-induced lesions and
there was no difference in the size or number of the lesions,
or the area of the colon affected, indicating a similar level of
macroscopic tissue damage (Figure 1D). The lesions were
mostly found in a 1-cm region of the proximal colon that
previously was designated as P2 and is located 2–3 cm from
the cecum.16 Microscopically, the lesions featured mucosal
surface erosion or ulceration with mixed inflammatory cell
infiltrate, resulting in mild-moderate to severe acute or
chronic inflammation, similar to our previous reports on
this model.16,18 A subset of up to 4 lesions/mouse devel-
oped mucinous or nonmucinous adenocarcinoma. The fre-
quency of cancer was 59% (13 of 22) in the homozygous
MccDIEC mice, 35% (7 of 20) in the heterozygous knockout
MccDIEC/WT, and 19% (8 of 42) in the Mcc-expressing
genotype controls (combined MccF/F and MccF/WT). Loss of
Mcc expression increased carcinogenesis (P ¼ .002; MccDIEC
vs Mcc-expressing controls). This was owing to an
2019 New Pathways in Colon Inflammation and Cancer 821increase of cancer in MccDIEC males (10 of 12) compared
with Mcc-expressing males (5 of 16; P ¼ .009). Overall,
cancer was more common in sulindac-treated males (21 of
41) than in females (7 of 43) (P ¼ .001). This was statis-
tically significant in the 13 MccDIEC mice with cancer (10 of
12 males vs 3 of 10 females; P ¼ .03), but not in the Mcc-
expressing group with only 8 cancers (5 of 16 males vs 3 of
26 females; P ¼ .22). Representative adenocarcinoma is






































































Drug-Induced Colon Lesions Show
Up-Regulation of Proinflammatory Genes and
Down-Regulation of b-Catenin Target Genes
To determine gene expression changes in the earlier
lesions we conducted transcriptome profiling after 10
weeks of sulindac exposure. The surface mucosa was har-
vested from proximal (P1, P2) and distal colon and micro-
dissected separately from the macroscopic lesions.


















































822 Currey et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 4compared with matching normal tissue (Supplementary
Tables 1–3). There were no significant differences
between the genotypes for the most up-regulated genes
listed in Table 1 (>12-fold in MccDIEC mice) when the
lesions of MccF/F and MccDIEC mice were compared and data
were corrected for multiple testing. Validation of selected
genes was performed with quantitative polymerase chain
reaction (qPCR) in different regions of the colon (Figure 2).
Many of the highly up-regulated genes identified in this
study have been associated previously with inflammation or
carcinogenesis24,25 and were found in both MccDIEC and
MccF/F mice. They included S100A8/A9 (calprotectin),
Mmp13 and other Mmps, Tgfb, Tnfa, Cox2 (Ptgs2), the
interleukin 1 family of cytokines (Ilb, Ila, Il33, Il1f9), and
other inflammatory or immunosuppressive factors (Cxcl2/
Mip2, Il6, Cxcl1, Cxcl9, Cxcr2, Ido1, Pd-l1/Cd274), as well as
the free radical nitric oxide–producing enzyme iNos2.
Epithelial mesenchymal transition (EMT)-related factors
included Tgm2, Hif1a, Plaur, Plau, Dcn, Hgf, Grem1, Vim, and
Fn1. Gene set enrichment analysis (GSEA) of hallmark
pathways26 showed up-regulation of several inflammation
and cancer-associated pathways (Table 2) that overlap with
the mesenchymal subtype of colorectal cancer known as
consensus molecular subtype 4 (CMS4).27 The shared up-
regulated pathways were EMT, inflammatory response,
angiogenesis, complement, and transforming growth factor
b signaling (Table 2).27
Another shared feature with CMS4 was the absence of
b-catenin pathway hyperactivation in both genotypes.
b-catenin target genes Lgr5 and Axin2 actually were down-
regulated in the lesions compared with matching normal
tissue from control-fed mice (Figure 2), similar to our pre-
vious report in Hif1a-deficient and WT mice.18 Lgr5
expression is a key marker of colon stem cells28,29 and loss
of these cells was reported previously in dextran sodium
sulfate (DSS)-induced colitis.30 The cancers showed no evi-
dence of b-catenin nuclear localization and both E-cadherin
and b-catenin staining was strong in the membrane of the
cancer cells in Mcc-expressing and Mcc-deficient mice
(Figure 3A–D). Thus, cancer in this model is not driven by
b-catenin hyperactivation, and down-regulation of Lgr5Figure 1. (See previous page). MCC deficiency drives inflamm
induced macroscopic tissue damage in the mouse colon. (A)
MccF/F mouse line (B6.Cg-Mcc<tm1Maija>/Ausb). In cre-expres
Mcc exons 1–3 of the Mcc-201 isoform and the second includes
of full-length Mcc expression in the colon mucosa harvested fr
with MccF/F (F/F) mice, as determined by triplicate qPCR. A 2-t
icance. Three mice were analyzed for each colon region. Erro
proliferating, BrdU-positive, epithelial cells is reduced in MccD/D
2-tailed unpaired t test was used to determine statistical signific
Error bars indicate the means with SD. (D) The number and size
MccDIEC/WT, MccF/F, and MccF/WT (F/þ) mice. Image shows t
methylene blue–stained tissue (circles and arrow), in a section o
represents the number and total area of lesions for a single mous
with equal SD was used to determine statistical significance.
adenocarcinoma harvested from a MccDIEC mouse exposed to
mouse (left). Original magnification, 50. CDS, coding sequen
rescent Protein; FRT, Flippase Recombinase Target; loxP, Lo
Phosphoglycerate kinase; P1, P2, proximal colon mucosa; SA,expression suggests loss of colon stem cells and lack of
regenerative potential in the inflammatory lesions.
Among the few highly down-regulated genes were
Cyp2c67, Cyp2c68, Cyp2c40, and Cyp2c69 (5- to 12-fold)
from the cytochrome P450 cluster on chromosome 19,
which are orthologues of the human drug response gene
CYP2C9. Expression of aryl hydrocarbon receptor (Ahr),
another important drug response gene, was not altered in
the lesions. However, there was an increase of cytoplasmic
aryl hydrocarbon receptor (AHR) protein expression in the
normal-appearing colon epithelium, which is known to
absorb sulindac and its metabolites (Figure 3E–G).16Inflammation Is Associated With Suppression of
DNA Repair Pathways in Mcc-Deficient Mice
Although strong cancer-promoting genes and pathways
were highly activated in the colonic lesions of both genotype
groups (Tables 1 and 2), only 19% of Mcc-expressing con-
trols developed cancer compared with 59% of Mcc-deficient
mice. A significant difference between the 2 genotypes was
in signatures of DNA repair, DNA replication, and cell-cycle
regulation. GSEA analysis showed that the hallmark path-
ways G2M checkpoint, E2F targets, Myelocytomatosis
oncogene cellular homolog (MYC) targets, and DNA repair
were down-regulated in the lesions of Mcc-deficient mice
compared with the lesions of Mcc-expressing mice (Table 2).
This is consistent with the previously identified role of MCC
in the DNA damage response.8
Further analysis of the DNA repair pathway data iden-
tified 29 genes that were down-regulated significantly in the
lesions of Mcc-deficient mice (Figure 4A). These included
the DNA mismatch repair (MMR) genes Msh3, Msh2, Mlh1,
Mlh3, and Pms2. The baseline expression levels of MMR
genes were similar between different regions of the colon
within each group of control-fed mice (Figure 2). Msh2
expression was slightly higher in the colon of control-fed
MccDIEC mice than in Mcc-expressing mice. We analyzed
the lesions and cancers for microsatellite instability (MSI) of
mononucleotide repeats, a known marker of complete MMR
deficiency,31,32 but no instability was found (data notation-associated cancer but does not increase sulindac-
The Mcc targeting vector construct was used to generate the
sing mice, 2 truncated transcripts are expected; one includes
Mcc exon 1 of the Mcc-202 isoform. (B) Significant reduction
om MccDIEC (DIEC) and MccDIEC/WT (DIEC/þ) mice compared
ailed unpaired t test was used to determine statistical signif-
r bars indicate the means with SD. (C) The percentage of
(D/D) mouse colon crypts compared with their WT siblings. A
ance. Three mice/group and 20 crypts/mouse were analyzed.
of drug-induced inflammatory lesions were similar in MccDIEC,
he macroscopic appearance of the drug-induced lesions in
f the proximal colon containing the V-shaped folds. Each dot
e; 19–22 mice/group were analyzed. A 2-tailed unpaired t test
Error bars indicate the means with SD. (E) H&E image of an
sulindac (right) and matching normal colon from a control-fed
ce; dist, distal colon mucosa; EGFP, Enhanced Green Fluo-
cus of Crossover in P1; Neo, neomycin; pA, poly-A; PGK,
splice acceptor site; SD, splice donor site.
Table 1.Altered Expression of the Most Highly Affected Genes Is Similar in Drug-Induced Colon Lesions of MCCDIEC and
MCCF/F Mice





Mptx1; mucosal pentraxin 1 Down 184.9 90.4
S100a8; calgranulin A Up 176.9 59.4
Mmp13; matrix metallopeptidase 13 Up 165.5 93.6
Il1b; interleukin 1b Up 134.9 64.8
Il1a; interleukin 1a Up 122.4 62.4
LincRNA identified by NONCODE; TC1300000114.mm.1b Up 109.7 54.8
S100a9; calgranulin B Up 106.7 29.1
Mptx2; mucosal pentraxin 2 Down 101.2 45.3
Mmp10; matrix metallopeptidase 10 Up 87.6 46.6
Ptgs2; prostaglandin-endoperoxide synthase 2 Up 74.2 38.4
Retnlg; resistin-like g Up 60.4 10.4
Gp49a; glycoprotein 49 A Up 56.9 17.9
Lilrb4; leukocyte Ig-like receptor, subfamily B, member 4 Up 47.8 17.8
Clec7a; C-type lectin domain family 7, member a Up 46.0 26.0
Cxcl9; chemokine (C-X-C motif) ligand 9 Up 41.9 54.6
Irgb6; Tgtp2, T-cell–specific GTPase 2 Up 30.6 35.7
Stfa2l1; stefin A2 like 1 Up 28.6 9.0
Nos2; nitric oxide synthase 2, inducible Up 25.2 17.5
Cxcl2; chemokine (C-X-C motif) ligand 2, Mip2 Up 24.8 8.4
Steap4; STEAP family member 4 Up 23.6 15.3
Olr1; oxidized low density lipoprotein (lectin-like) receptor 1 Up 23.2 4.8
Gbp2; guanylate binding protein 2 Up 23.0 18.6
Irga family member; F830016B08Rik Up 22.2 17.5
Ly6c2; lymphocyte antigen 6 complex, locus C2 Up 21.4 17.4
Tgm3; transglutaminase 3, E polypeptide Down 20.9 16.1
Mmp12; matrix metallopeptidase 12 Up 19.9 8.2
F3; coagulation factor III Up 19.4 11.2
Mrgpra2a; MAS-related GPR, member A2A Up 19.0 4.0
Irg1; immunoresponsive gene 1 Up 18.5 6.6
Irga6; Iigp1, interferon inducible GTPase 1 Up 17.8 21.3
Dcn; decorin Up 17.3 13.6
Il1f9; interleukin 1 family, member 9 Up 17.3 5.0
Akt3; thymoma viral proto-oncogene 3 Up 17.2 19.5
Reg3b; regenerating islet-derived 3 b Up 16.9 28.7
Igsf6; immunoglobulin superfamily, member 6 Up 16.7 9.2
Reg3g; regenerating islet-derived 3 g Up 16.7 22.1
Sema3e; semaphorin 3E Up 16.2 6.7
Irgm3; Igtp, interferon g induced GTPase Up 15.9 15.2
LincRNA identified by NONCODE; TC0700002949.mm.1 Up 15.3 4.6
LincRNA identified by NONCODE; TC1800000456.mm.1 Up 15.1 21.0
LincRNA identified by NONCODE; TC1900000899.mm.1 Up 15.1 6.8
Clec4e; C-type lectin domain family 4, member e Up 15.0 5.4
Irgb family member; Gm12185 Up 14.3 16.5
Osmr; oncostatin M receptor Up 13.9 9.5
Il33; interleukin 33 Up 13.6 5.4
NcRNA identified by NONCODE; TC0700004005.mm.1 Up 13.3 10.3
Il1rl1; interleukin 1 receptor-like 1 Up 13.3 9.1
Plek; pleckstrin Up 13.3 5.4
Irgb10; Gm12250 Up 13.1 15.7
2019 New Pathways in Colon Inflammation and Cancer 823
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Ifi204; interferon activated gene 204 Up 12.8 7.3
Sult1a1; sulfotransferase family 1A, phenol-preferring, member 1 Down 12.8 14.4
Ms4a4c; membrane-spanning 4-domains, subfamily A, member 4C Up 12.8 10.6
Gm10720; predicted gene 10720 Up 12.7 3.0 (NS)
Mnda; myeloid cell nuclear differentiation antigen Up 12.7 8.2
Cyp2c68; cytochrome P450, family 2, subfamily c, polypeptide 68 Down 12.6 12.4
Ly6c1; lymphocyte antigen 6 complex, locus C1 Up 12.3 11.9
Sequence 49 from patent WO2005040187 Up 12.2 5.1
Gpr110; G-protein–coupled receptor 110 Up 12.2 13.0
Ly6g; lymphocyte antigen 6 complex, locus G Up 12.1 9.8
Adm; adrenomedullin Up 12.0 4.7
NOTE. The genes are ranked according to the absolute fold-change of expression (>12-fold) in the lesions vs matching normal
tissue in MCCDIEC mice. The range of significant Q values for these genes is 1.7  10-11-0.0001 (complete data are shown in
Supplementary Tables 1, 2, and 3).
aFold change compared with control-fed mice of the matching genotype, with a significant Q value (<0.05).
bAffymetrix probe set ID.
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deficiency of MMR.
A further 12 of the down-regulated genes were associ-
ated with the homologous recombination repair (HR)
pathway, such as Atm, Rpa2, and Rad. This profile of gene
expression indicates a generalized defect of DNA repair
involving different types of DNA damage. To understand
how a lack of MCC is disrupting the response to inflamma-
tion, we used H2O2 to mimic the inflammation-induced free
radical generation in mouse embryo fibroblasts (MEFs)
prepared from whole-body knockout MccD/D mice and their
WT siblings. MccD/D and WT MEFs were treated with H2O2
for 1–6 hours and the cell lysates then were examined for
RNA or protein expression of DNA repair genes and markers
of the DNA damage response. Expression of Msh3, Msh2,
Mlh1, and Atm was reduced significantly in MccD/D MEFs
compared with WT cells with 4- or 6-hour H2O2 exposure
(Figure 4B). The WT MEFS showed phosphorylation of the
checkpoint kinase (CHK)1 and CHK2 after H2O2 addition.
This is consistent with activation of DNA damage response
via the serine/threonine–protein kinases ataxia telangiec-
tasia and Rad3-related (ATR) and ataxia telangiectasia
mutated (ATM) (Figure 4C). MccD/D MEFS also showed
phosphorylation of CHK2, which may indicate additional
signaling through other kinases apart from ATM.33 In
contrast, the ATR-related signaling pathway, which leads to
phosphorylation of CHK1 and the repair of DNA single-
strand breaks (SSBs), was markedly suppressed. MCC
expression itself also was induced by H2O2 exposure in WT
MEFs (Figure 4C).
Surprisingly, we identified an increase in cell-cycle S-
phase in MccD/D cells treated with H2O2 for 1–6 hours.
There was also a sustained S-phase in cells allowed to
recover in fresh medium after a 2-hour H2O2 exposure
(Figure 4D). This led us to ask whether the increase in S
phase after the DNA damage associated with MCC loss wasowing to an active or arrested S-phase. We performed
Western blot for the key cell-cycle regulator retinoblastoma
(RB) and phosphorylated RB as a measure for an active S-
phase. The WT MEFs responded to H2O2 with a loss of
phosphorylation of RB within 1 hour. By contrast, MccD/D
MEFS showed sustained, or a slight increase in, phosphor-
ylation of phosphorylated RB after exposure to H2O2
(Figure 4C). Consequently, it appears that there is loss of
DNA damage response signaling in MccD/D MEFS that may
be accompanied by sustained proliferation. To confirm these
observations, we analyzed whether MCC loss also leads to a
relative increase of S-phase in UV-treated HCT116 cells,
which express endogenous MCC (Figure 4D). Both non-
targeted (NT) and MCC-knockdown (KD) cells showed a
subtle increase in S-phase 24 hours after 10 J/m2 UV
treatment. However, the MCC-KD cells showed a trend for a
more persistent increase in S-phase fraction at 48 hours that
continued until 72 hours after treatment.
Exposure to mutagens during an active S-phase means
that there is a greater likelihood that the cells sustain DNA
damage, which then may be integrated into the genome
through low-fidelity repair mechanisms. To test whether
MCC-knockdown cells sustain greater DNA damage in S-
phase, we subsequently treated HCT116 cells with SN38,
which is a metabolite of the chemotherapy drug irinotecan
and causes SSBs. A comet assay showed that MCC-
knockdown cells have greater DNA damage compared
with NT cells after treatment with SN38 (Figure 4E). DNA
damage also was increased in H2O2-treated Mcc
D/D MEFS
with defective CHK1 signaling. There was a strong increase
of gamma histone 2AX (gH2AX), whereas in WT MEFs the
increase was minimal (Figure 4C). gH2AX is a marker of
double-strand break damage that can develop from SSB
through DNA replication when SSB repair is deficient.
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P = .02P = .02P < .05
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g–Induced Guanosine Triphosphatase Response
to Colon Barrier Destruction
Because the impact of Mcc deficiency on carcinogenesis
was shown only in the drug-induced lesions, we proceeded
to investigate if sulindac-induced colon inflammation is
similar or has some unique features compared with another
model of colon inflammation. Search of the literature for a
comparable gene profiling study identified a report on DSS
colitis that develops in the mouse mid-distal colon.34 The
gene profiles were strikingly similar between the 2 models,
although the time scale of drug exposure was different, 6
days of DSS vs 10 weeks of sulindac (Figure 5A). Overall, the
2 studies were correlated positively (r ¼ 0.55; P < 2e-16)
and 1602 differentially expressed probe sets were highly
correlated (r ¼ 0.82). This is compatible with the concept
that both models involve colon barrier destruction.
The top 2 GSEA hallmark pathways26 activated in our
study were interferon g (IFNg) response and EMT (Table 2).
These indicate strong responses to colon barrier destruction
and bacterial invasion of the underlying tissue layers.25,35 A
prominent feature of the colon lesions in both genotype
groups was the induction of at least 28 IFNg-induced gua-
nosine triphosphatase (GTPase) genes, usually thought to be
associated with the host response to external pathogens and
not previously recognized in the mouse colon. Several
clusters of these genes were identified on chromosomes 3,
5, 7, 11, and 18, which also included long noncoding RNAs
(Table 3).36 Sixteen of the up-regulated genes represent the
Irg (p47-GTPase) subfamily, of which only the IRGM and
IRGC genes have been retained through evolution in human
beings. IRGM is a candidate for the Crohn’s disease sus-
ceptibility locus.37 We identified only 11 IFNg-induced
GTPase genes in the previous generation Affymetrix array
(Santa Clara, CA) used for the DSS colitis study, but most of
them also were up-regulated in that study (Figure 5A).
Therefore, up-regulation of IFNg-induced GTPases is not
unique to sulindac-induced colon inflammation.
Two of the genes Irga6 (Iigp1) and Irgb6 (Tgtp2) were
selected for validation by qPCR in different parts of the
colon. The level of expression was variable but was
increased in the sulindac-induced lesions (Figure 5B). To
investigate the possibility that the high expression of these
genes was related to an undetected pathogen infection in
the animals, we analyzed colon specimens from 3 experi-
ments over 4 years and found that Irgb6 and Irga6 genes
were consistently up-regulated in sulindac-induced lesions,
similar to the chemokine Mip2 (Figure 5C). We then treated
CT26 mouse colon cancer cells in vitro with lipopolysac-
charide, a component of the bacterial membrane. This
treatment also induced the expression of Irgb6, Irga6,
and Mip2 (Figure 6A), similar to the induction ofFigure 2. (See previous page). Validation of altered gene ex
harvested from ileum, proximal P1 and P2, proximal P2 lesions
diet (3–6 mice/group). In sulindac-fed mice, P2 refers to macro
sions. RNA expression was analyzed by triplicate qPCR and nor
in the P2 region. A 2-tailed Mann–Whitney test was used to de
with SD. mRNA, messenger RNA.proinflammatory signaling shown previously in vitro by
sulindac sulfide.17,18 Therefore, the strong expression of
multiple IFNg-induced GTPases is a previously unrecog-
nized feature of mouse colitis that is not necessarily related
to an external pathogen infection, but can be triggered by
gut bacteria invading the submucosa and causing inflam-
mation after sulindac-induced initial injury. Proin-
flammatory factors also can induce the same response
in vitro.
We analyzed the protein expression of 2 of the highly
up-regulated genes Irga6 and Irgm3. There was no expres-
sion of Immunity-related GTPase A6 (IRGA6) in the normal
colon of drug-treated or untreated mice, but it was present
in most of the lesions. There was strong cytoplasmic
expression in the mesenchymal cells, such as fibroblasts/
myofibroblasts and macrophages, in the areas of acute
inflammation associated with erosions or ulceration of the
mucosa (Figure 6). There was also strong cytoplasmic
expression of enterocytes in the colonic epithelium at the
edges of these areas of ulceration, but very weak expression
in the cancer cells. There was no expression of IRGA6 in the
lymphocytes or neutrophils in the inflamed tissue. Immu-
nity-related GTPase M3 (IRGM3) expression also mostly was
absent in the normal colon apart from isolated plasma cells
and endothelium of blood vessels. Inflammation induced
IRGM3 expression in the colonic epithelium and also was
seen in infiltrating plasma cells and macrophages (Figure 6).
Similar patterns of IRG protein expression were found in
both MccDIEC and MccF/F mice.
Discussion
This study shows that loss of MCC expression promotes
inflammation-associated cancer in the mouse colon. Despite
a strong cancer-promoting phenotype in the inflamed
tissue in both genotypes, only 19% of the genotype controls
(MccF/F) developed malignant tumors, compared with 59%
of the MccDIEC mice. The background cancer frequency is
comparable with WT mice exposed to sulindac (5%–
16%)16,18 or DSS (17%–22%).38 The gene profiles in the
inflamed tissue showed a much wider spectrum of the
signaling pathways than previously recognized, including
novel coding and noncoding genes. The data implicate
activation of cancer-promoting genes and pathways in
producing a premalignant tissue microenvironment, which
does not involve b-catenin hyperactivation. We found that
b-catenin protein expression was mainly localized in the
epithelial cell membrane in the tumors. The lack of nuclear
b-catenin hyperactivity was shared by both MccF/F and
MccDIEC mice in our study and is similar to the mesenchymal
CMS4 subtype in human beings, which may comprise up to
23% of colorectal cancers.27 There are also other important
similarities between sulindac-induced inflammation andpression in inflammatory lesions. The mucosal lining was
, and distal colon of mice given either sulindac or the control
scopically normal-appearing tissue adjacent to the visible le-
malized to Gapdh. P values are shown only for the differences
termine statistical significance. Error bars indicate the means
Table 2.Hallmark Pathways for DNA Repair, G2M Checkpoint, MYC Targets and E2F Targets Are Up-regulated in MccF/F Mouse Lesions but Down-regulated in MccΔIEC


















Interferon g response 0.80 0 0.78 0 0.31 0.004
Epithelial mesenchymal transition 0.77 0 0.78 0 0.57 0
Allograft rejection 0.76 0 0.75 0 0.47 0
Interferon a response 0.80 0 0.77 0 0.24 0.29 NS
Inflammatory response 0.69 0 0.74 0 0.57 0
IL6 JAK STAT3 signaling 0.76 0 0.78 0 0.61 0
TNFa signaling via NF-kB 0.68 0 0.75 0 0.71 0
Angiogenesis 0.68 0 0.77 0 0.53 0
TGFb signaling 0.57 0 0.62 0 0.55 0
Apical junction 0.54 0 0.61 0 0.42 0
Apical surface 0.59 0 0.54 6.84E-04 0.32 0.097 NS
Apoptosis 0.56 0 0.59 0 0.46 0
KRAS signaling up 0.55 0 0.61 0 0.47 0
IL2 STAT5 signaling 0.55 0 0.58 0 0.43 0
Hypoxia 0.51 0 0.60 0 0.52 0
Complement 0.62 0 0.66 0 0.49 0
Coagulation 0.60 0 0.66 0 0.49 0
PI3K Akt mTOR signaling 0.44 7.8E-04 0.38 0.017 0.23 0.260 NS
DNA damage and checkpoints
G2M checkpoint 0.53 0 -0.30 0.093 NS -0.62 0
DNA repair 0.18 0.94 NS -0.39 0.008 -0.45 0
Mitotic spindle 0.48 0 0.36 0.013 -0.27 0.043
UV response down 0.47 0 0.51 0 0.37 4.1E-04
Cell cycling and cell growth
MYC targets v1 0.66 0 -0.34 0.024 -0.70 0
MYC targets v2 0.52 1.8E-04 -0.40 0.037 -0.72 0
E2F targets 0.55 0 -0.48 0 -0.73 0
Metabolism
mTORC1 signaling 0.56 0 0.39 0.004 -0.34 6.0E-04
Unfolded protein response 0.43 9.7E-04 -0.25 0.494 NS -0.50 0
Adipogenesis -0.37 0.004 -0.45 0 -0.36 4.5E-04
Fatty acid metabolism -0.45 0 -0.52 0 -0.40 1.6E-04
Peroxisome -0.47 0 -0.49 0 -0.29 0.075 NS
Oxidative phosphorylation -0.40 0.001 -0.66 0 -0.66 0
NOTE. Positive ES (maximum, 1) indicates up-regulation of pathway and negative values show down-regulation. Hallmark pathways for G2M checkpoint, DNA repair, MYC
targets v1, MYC targets v2 and E2F targets are down-regulated in MccDIEC lesions compared to MccF/F lesions.
ES, enrichment score; FDR, false discovery rate; IL, interleukin; JAK, Janus kinase; mTOR, Mechanistic Target of Rapamycin Kinase; NF-kB, nuclear factor-kB; PI3K,
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Figure 3. Tissue expres-
sion of b-catenin, E-cad-
herin, and AHR in the
inflamedmousecolonand
cancers. (A and B) Cancer
cells maintain strong mem-
branous b-catenin (b-CAT)
expression. (arrows). (C and
D) Cancer cells maintain E-
cadherin (E-CAD) expres-
sion (arrows). (E–G) AHR
was expressed diffusely
in the cytoplasm of
normal colonic epithelium
and was increased in
mice exposed to sulindac.
AHR expression was pre-
sent in the inflammation-
associated adenocarci-
noma. Original magnifica-
tion: (A, B, E, F, G
inset)400, (C andD)200,
and (G)100.
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pathways are the same (EMT, Inflammatory Response,
Angiogenesis, Complement and TGF Beta Signaling). In
addition, down-regulation of MYC target genes is charac-
teristic for both MccDIEC mouse lesions and CMS4.
Loss of MCC causes a slight decrease in epithelial cell
proliferation in the normal colon, which could be related to
a small impairment of the DNA damage response to a
background level of DNA SSBs occurring in the healthy
colon, but has no significant phenotypic effect in the adult
mouse or during development.39 In stressed inflammatoryconditions a lack of MCC causes subtle but widespread
down-regulation of pathways involved with DNA damage
and replication, such as the G2M checkpoint and DNA repair
(Table 2). In the same conditions, MCC-expressing mice
showed up-regulation of these pathways. This up-regulation
is a normal response to DNA damage and replication stress
caused by reactive oxygen and nitrogen species, which are
generated by the inflammation.40 Oxidative stress itself also
is known to impair MMR protein function, which is thought
to cause low-level MSI associated with chronic inflamma-
tion.41 The gene expression changes observed here were





















































































































































WT KO WT KO WT KO WT KO WT KO
0 2 22 h Passage 1 Passage 2
400 μM H2O2 fresh medium, no H2O2
C
P = .03 P = .03
WT KO WT KO WT KO WT KO






















































WT KO WT KO WT KO
0 4 6 hr H2O2 
WT KO WT KO WT KO
0 4 6 hr H2O2 
WT KO WT KO WT KO
0 4 6 hr H2O2 
WT KO WT KO WT KO
0 4 6 hr H2O2 
WT KO WT KO WT KO
0 4 6 hr H2O2 
P = .03























P < .0001P < .0001
500 nM SN38 1 μM SN38Untreated HCT116 cells







































































0  1  2  4 0  1  2  4 hr
WT KO
RB









0  1   2  4 0  1  2  4 hr
WT KO



























































2019 New Pathways in Colon Inflammation and Cancer 829
830 Currey et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 4associated primarily with Mcc deletion in the inflamed colon
tissue. It remains to be determined whether MCC silencing
contributes to the MSI-low phenotype in chronic IBD.
Complete MMR deficiency also can cause a loss of the G2/M
checkpoint after N-methyl-N0-nitro-N-nitrosoguanidine or
tioguanine-induced DNA damage.42 However, it is unclear
whether our observations in MccDIEC mice are related to the
same cellular process.
Curiously, we also observed down-regulation of E2F
target genes by GSEA of MccDIEC mice (Table 2). The E2F
transcription factor family plays a central role in the
sequential expression and repression of genes required for
cell-cycle progression, DNA repair, and replication. For
example, MMR and many other DNA repair genes are
transcribed by E2F.43 Sustained E2F activity is a key cellular
mechanism to allow cells to recover from DNA damage
induced by replication stress and is mediated by activation
of CHK1.44–46 Because we showed that the absence of MCC
prevented the phosphorylation of CHK1 in MEF cells
exposed to the DNA damaging agent H2O2, it is possible that
the MccDIEC mice failed to activate an E2F transcriptional
cascade in response to excessive DNA damage and replica-
tion stress in the inflamed lesions. This suggests a role for
MCC in the cell-cycle S-phase checkpoints that have evolved
to respond to potential failures in DNA repair and replica-
tion. Defective E2F signaling contributes to genomic insta-
bility, a recognized hallmark of cancer.47
Our study also described a previously unrecognized
feature of mouse colitis, coordinated up-regulation of 28
members of the IFNg-induced GTPase superfamily that de-
fends mammalian cells against a diverse group of invading
pathogens, such as intracellular bacteria and protozoa.48–51
Here, this up-regulation was seen in the absence of external
pathogen involvement in the inflamed colon and was
restricted to immediate proximity of the damaged epithelial
barrier that allows translocation of the gut microbiome. This
feature has become evident in our study by using the latest
generation microarrays that provide a much wider coverage
of the genome. In the mouse there are 3 highly complexFigure 4. (See previous page). MCC deficiency causes down
increases SSBs and double-strand breaks through comprom
sulindac drug-induced (SUL) lesions and the matching tissue fro
down-regulated significantly in the lesions of MccDIEC mice. Low
and red, respectively. Genes were assigned to the correspondi
excision repair; HR, homologous recombination repair; TC-NE
nonhomologous end-joining; TLS, translesion synthesis; and
determined using limma via the limmaGP tool in GenePattern.64
Atm gene expression in MEFs treated with 400 mmol/L H2O2. T
the same MEF cell lines. RNA expression was analyzed by tripl
between WT and knockout (KO) was determined using the 2-tail
(C) MCC deficiency causes loss of Chk1-S345 phosphorylation
treated with 400 mmol/L H2O2. The graphs show quantification
tistical significance was determined using the 2-tailed Kruskal–
MCC deficiency or KD causes an increase in cell-cycle S-phase
recover in fresh medium after a 2-hour H2O2 treatment (400 mm
nificance was determined using the 2-tailed Mann–Whitney and K
indicate means with SD. (F) SN38 treatment leads to higher leve
control cells. Comets (N ¼ 35–83) scored from 3 independent ex
unpaired t tests were performed (95% CI) to determine the statis
means with SD.subfamilies, Irg, Gvin, and Gbp, each with different roles and
functions. They have not been linked with carcinogenesis,
although other GTPases, such as Ras, Rac, and Rho, are well-
known oncogenes and EMT promoters when mutated or
up-regulated.
In the human colon, overexpression of a germline variant
of the IRGM gene has been associated with susceptibility to
Crohn’s disease–associated chronic inflammation.52,53 In the
mouse, IRG protein activation is more complex with 2
groups of factors, the regulatory GMS (IRGM1–3) and the
effector GSK subfamily (multiple IRGA and IRGB proteins),
which have complementary roles. Expression of some of the
IRG proteins has been characterized in vitro in the context
of intracellular bacterial or parasite infections and activa-
tion of the NLRP3 inflammasome.50 Further studies are
required to determine the functional consequences of the
concordant expression of the Irg/noncoding RNA clusters in
the inflamed tissue and whether there is any similarity to
the defect of intracellular bacterial clearance in Crohn’s
disease that increases inflammation.52,53 It also is possible
that the composition of the gut microbiome can affect the
level of expression/activation of the IRG proteins and
the severity of inflammation. It is well known that the
severity and timing of experimental colitis can vary
depending on the dosage and duration of drug exposure,
mouse strain, housing conditions, and composition of the
gut microbiome.54 Therefore, these genes could be pursued
further as potential markers of a pathogenic response to
drug toxicity or severity of inflammation in the colon and its
interplay with the gut microbiome.
It is likely that the strong inflammatory EMT and IFNg
response observed in the 10-week lesions was caused by
colon barrier destruction. However, sulindac exposure
clearly was the trigger, possibly by causing the initial drug
toxicity and erosion of the surface mucosa through
increased AHR signaling. Sulindac is a ligand of AHR and can
cause proinflammatory AHR, nuclear factor-kB (NFkB), and
AP-1 Transcription Factor Subunit cJUN (cJUN) signaling
in vitro that is reversed when AHR is knocked down.18,55 We-regulation of DNA repair genes in the inflamed colon and
ised DNA damage signaling. (A) Transcriptome analysis of
m control-fed mice (CON). A subset of DNA repair genes was
and high expressed genes in the heatmap are shown in blue
ng DNA repair pathways: MMR, mismatch repair; BER, base
R, transcription coupled nucleotide excision repair; NHEJ,
FA, Fanconi anemia pathway. Statistical significance was
(B) Mcc deletion causes down-regulation of Msh2, Msh3, and
he graphs show values from 3 independent experiments with
icate qPCR and normalized to Gapdh. Statistical significance
ed Kruskal–Wallis test. Error bars indicate the means with SD.
and an increase of gH2AX and RB phosphorylation in MEFs
of protein expression from 3 independent experiments. Sta-
Wallis test. Error bars indicate the means with SD. (D and E)
in MEFs treated with 200 mmol/L H2O2 and in MEFs allowed to
ol/L), as well as in UV-treated HCT116 cells. Statistical sig-
ruskal–Wallis tests (3–4 independent experiments). Error bars
ls of DNA damage in MCC-KD HCT116 cells than in NT vector
periments were combined and plotted in a dot plot. Two-tailed




































































































































































































































































Figure 5. Gene expression profiles are similar between DSS colitis and sulindac-induced colon inflammation. (A) Global
comparison of gene expression in sulindac-induced lesions (MccF/F mice) with the DSS colitis data reported by Fang et al34 in
2011. Log fold-change between the end points and controls were plotted for probe sets that were differentially expressed in
both of the studies (blue, N ¼ 1602), this study only (green, N ¼ 702), or Fang et al34 study only (pink, N ¼ 5637). IFNg-induced
GTPases that were common for both studies are highlighted in black. A total of 10,957 probe sets that were not differentially
expressed in either study were not plotted. (B) Validation of up-regulated Irga6 and Irgb6 expression in the inflammatory le-
sions (3–6 mice per group). RNA expression was analyzed by triplicate qPCR and normalized to Gapdh. A 2-tailed
Mann–Whitney test was used to determine statistical significance. Error bars indicate the means with SD. (C) Expression of
Irga6, Irgb6, and the chemokine Mip2 (positive control of inflammation) in the lesions from 3 independent mouse experiments
(3 mice/experiment; 3 technical replicates/lesion also shown). Lesions and proximal control tissue were analyzed from the
same mice. P values are shown only for the differences in the P2 region. Gene expression was analyzed by qPCR, and
normalized to Gapdh expression. A 2-tailed Wilcoxon matched-pairs signed-rank test was used to determine statistical sig-
nificance. Error bars indicate the means with SD. Exp, Experiment; prox, proximal colon adjacent to lesions.
2019 New Pathways in Colon Inflammation and Cancer 831
Table 3.Differential Expression of IFNg–Induced GTPase Genes and Co-localizing ncRNAs in the Drug-Induced Colon
Lesions From MCCF/F Mice, Compared With Matching Normal Tissue
Affymetrix ID Folda Direction Q valueb Chromosomal locationc Gene symbol or name
TC0700003994.mm.1 2.8 Down 0.048 7: 105,852,518–105,855,944 LincRNA identified by NONCODE
TC0700003996.mm.1 6.1 Up 3.4E-06 7: 105,895,118–105,953,970 VLIG1 (Gm4070)
TC0700003998.mm.1 2.5 Down 0.045 7: 106,076,751–106,084,046 VLIG1 pseudogene (Gm8979)
TC0700004000.mm.1 2.8 Down 0.048 7: 106,113,896–106,117,322 LincRNA identified by NONCODE
TC0700004002.mm.1 7.6 Up 4.2E-06 7: 106,156,556–106,215,326 Gvin1
TC0700004003.mm.1 6.7 Up 3.0E-06 7: 106,185,743–106,190,099 Gvin1 pseudogene (Gm18853)
TC0700004004.mm.1 5.5 Up 1.5E-05 7: 106,200,812–106,203,310 NcRNA identified by NONCODE
TC0700004005.mm.1 10.3 Up 6.4E-06 7: 106,207,673–106,210,791 NcRNA identified by NONCODE
TC1100002641.mm.1 3.1 Up 1.2E-07 11: 48,861,968–48,871,683 Irgm1 (Lrg47)
TC1100002642.mm.1 2.8 Up 7.7E-03 11: 48,887,422–48,902,152 Irgb8-b9 (Gm5431)
TC1100002643.mm.1 16.5 Up 5.4E-07 11: 48,904,656–48,994,172 Irgb1-b2 (Gm12185) and Irgb6* (Tgtp1)
TC1100004292.mm.1 3.1 Up 1.3E-04 11: 48,946,150–48,979,398 Irgb3-b5* (9930111J21Rik1)
TC1100002647.mm.1 2.8 Up 8.2E-04 11: 49,014,075–49,014,785 LincRNA identified by NONCODE
TC1100002648.mm.1 3.3 Up 1.0-E04 11: 49,015,874–49,051,242 Irgb4-b5 (9930111J21Rik2)
TC1100002649.mm.1 35.7 Up 6.6E-07 11: 49,057,194–49,064,212 Irgb6 (Tgtp2)
TC1100000496.mm.1 2.2 Up 2.12E-5 11: 48,978,889–49,135,387 Irgd (Ifi47; Irg47)
TC1100000681.mm.1 15.7 Up 1.9E-08 11: 58,183,843–58,190,198 Irgb10 (Gm12250)
TC1100004265.mm.1 15.2 Up 1.6E-07 11: 58,199,556–58,207,592 Irgm3 (Igtp)
TC1100004266.mm.1 3.5 Up 8.5E-06 11: 58,199,618–58,222,779 Irgm2 (Iigp2)
TC1100000683.mm.1 6.5 Up 1.5E-05 11: 58,202,415–58,204,772 NcRNA identified by NONCODE
TC1800000606.mm.1 11.3 Up 5.4E-07 18: 60,212,077–60,247,820 Irga2 (Gm4951)
TC1800000607.mm.1 9.9 Up 1.1E-05 18: 60,220,843–60,222,058 Irga8 (Gm5970)
TC1800000608.mm.1 3.3 Up 2.8E-05 18: 60,257,748–60,288,497 NcRNA identified by NONCODE
TC1800001396.mm.1 10.5 Up 1.5E-05 18: 60,268,301–60,273,267 Irga3 (Gm4841)
TC1800000609.mm.1 17.5 Up 1.0E-05 18: 60,293,380–60,303,016 Irga4 (F830016B08Rik)
TC1800000610.mm.1 21.3 Up 2.3E-07 18: 60,376,028–60,392,634 Irga6 (Iigp1)
TC0300001444.mm.1 3.8 Up 6.5E-06 3: 142,493,978–142,522,344 Gbp5
TC0300001445.mm.1 8.8 Up 5.2E-07 3: 142,530,342–142,550,149 Gbp7
TC0300001446.mm.1 4.2 Up 2.0E-06 3: 142,560,026–142,573,209 Gbp3
TC0300001447.mm.1 18.6 Up 1.9E-07 3: 142,620,602–142,638,008 Gbp2
TC0500003729.mm.1 5.0 Up 9.9E-05 5: 105,014,150–105,139,540 Gbp8
TC0500003730.mm.1 5.3 Up 1.5E-06 5: 105,077,630–105,139,539 Gbp9
TC0500003731.mm.1 7.7 Up 4.1E-06 5: 105,115,767–105,139,586 Gbp4
TC0500002895.mm.1 8.1 Up 3.1E-06 5: 105,215,699–105,239,533 Gbp10
TC0500002896.mm.1 3.8 Up 4.3E-05 5: 105,323,042–105,346,472 Gbp11
NOTE. Gene nomenclature is from Lilue et al.36
LincRNA, Long intergenic non-coding RNA; LncRNA, Long non-coding RNA.
aFold-change in sulindac-fed mice compared with control-fed mice.
bQ value is the significance corrected for multiple comparisons.
cGenomic coordinates from Mouse Genome Assembly GRCm38.p4.
832 Currey et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 4showed previously that small lesions become visible and
show up-regulation of NFkB target genes after 1 week of
sulindac exposure.16,17 The tissue toxicity caused by
nonsteroidal anti-inflammatory drugs (NSAID) is well
documented in the human gastrointestinal tract.56 A germ-
line variant of CYP2C9 causes low activity of the enzyme
and susceptibility to NSAID–associated gastrointestinal
bleeding.57 We observed a coordinated decrease in the
expression of the drug response gene cluster Cyp2c67,
Cyp2c68, Cyp2c40, and Cyp2c69, which are orthologues ofhuman CYP2C9. Down-regulation of these genes also was
found in DSS colitis34 and thus may be more widely asso-
ciated with drug-induced colon barrier destruction rather
than being a sulindac-specific alteration.
This study has shown widespread similarities in the gene
expression profiles of sulindac and DSS-induced colitis.
Furthermore, similar to the azoxymethane/DSS model of
colon cancer, male mice are more susceptible than female
mice to cancer associated with sulindac-induced inflamma-
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834 Currey et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 4severe in the lower colon, this varies according to the
molecular weight of DSS. A lower molecular weight (5 kil-
odaltons) of DSS is absorbed in the proximal colon/cecum
and causes patchy lesions.59 Therefore, the localization of
sulindac-induced lesions in the mucosal folds of the prox-
imal colon may be a combination of mechanical and bio-
logical factors.
Taken together, this study has provided evidence for the
in vivo functional significance of MCC and has shown that
the MCC knockout defect can drive carcinogenesis in the
absence of b-catenin hyperactivity. It also has shown novel
insights into the complexity of the inflammatory microen-
vironment that predisposes to malignancy in colorectal
cancer.
Materials and Methods
Generation of New Mouse Lines
The Mcc-loxP mouse line (MccF/F) was generated by
Ozgene (Bentley, WA, Australia) (Figure 1A) and designated
B6.Cg-Mcc<tm1Maija>/Ausb. The 5’ and 3’ homology arms
for the Mcc targeting vector were generated by PCR
(Figure 1A). The first shared exon of the 2 main transcripts
Mcc-201 (exon 4) and Mcc-202 (exon 2) was replaced by a
partial complementary DNA (cDNA) modified from RIKEN
clone E330037C1 (RIKEN, Saitama, Japan). This contained
Mcc-201 exons 4–19, which correspond to Mcc-202 exons
2–17. The PGK-Neo selection, eGFP reporter, and STOP
cassettes were inserted downstream of the cDNA. The
targeting construct was electroporated into a C57BL/6
embryonic stem (ES) cell line, Bruce4.60 Homologous
recombinant ES cell clones were identified by Southern
hybridization and injected into blastocysts. Male chimeric
mice were obtained and crossed to C57BL/6J females to
establish heterozygous germline offspring on a C57BL/6
background. The germline mice were crossed to a ubiqui-
tous FLP C57BL/6 mouse line to remove the FRT flanked
selectable marker cassette. MCC expressed by the MccF/F
mice is driven from the endogenous Mcc-202 promoter but
partially derived from the cDNA sequence. The long isoform
Mcc-201 is not expressed in the colon of WT or MccF/F mice.
All subsequent breeding was performed at Australian
BioResources (Moss Vale, Australia) in specific pathogen-
free conditions, on a C57BL/6J strain background. MccF/FFigure 6. (See previous page). Inflammation induces strong
colonic epithelium. (A) Lipopolysaccharide (LPS) treatment in
chemokine Mip2 in mouse CT26 cells. The cells were treated
qPCR. mRNA levels were normalized to Gapdh. The graphs sh
analysis of variance with a post hoc test for significant means wa
the means with SD. (B–E) Immunohistochemical images of IRG
Expression in the cytoplasm of isolated plasma cells and endoth
(C) Strong expression in the stromal and epithelial cells in an are
expression in the stromal cells in an area of ulceration but we
expression of enterocytes in the colon epithelium (white arrow
cells away from inflammation (purple arrow) or in the neutrop
chemical images of IRGM3 staining in the mouse colon (MccF/F
endothelium of blood vessels but not in the healthy colonic ep
colonic epithelium. Expression also was seen in infiltrating plasm
Zeiss Axio A2 Digital microscope with EC Plan-NEOFLUAR ob
kochen, Germany). Original magnification, (E–G) 400, (B–D) mice were crossed with the cre-deleter mice (B6.C-Tg
[CMV-cre]1Cgn/J)61 to generate the whole-body knockout
line (MccD/D). The loxP-flanked region is deleted in cre-
expressing mice and translation is terminated after the
eGFP sequence. Two truncated fluorescent protein isoforms
are expected but the transcripts appear to be unstable with
no protein produced. Absence of the MCC protein was
confirmed by Western blot in MccD/D mice. The major or-
gans of four 40- to 47-week-old MccD/D mice were analyzed
by the Australian Phenomics Network (IMVS Veterinary
Pathology, Adelaide, Australia).
For the sulindac diet experiments, MccF/F were crossed
with mice carrying the Vilcre transgene (B6.SJL-Tg[vil-cre]
997Gum/J) (Jackson Laboratories, Bar Harbor, ME).23 A
2-generation breeding protocol produced 4 genotypes:
VilcreMccF/F (MccDIEC), VilcreMccF/WT (MccDIEC/WT), MccF/F,
and MccF/WT. The animal experimentation was approved by
the Garvan Institute Animal Ethics Committee.
For generation of MEF lines, MccD/WT mice were crossed
to obtain MccD/D and Mcc-WT embryos. MEFs were pre-
pared from 13.5-day-old embryos and serially passaged in
Dulbecco’s modified Eagle media with 10% fetal bovine
serum until they were immortalized.62 Experiments were
conducted with immortalized MEFs.
Genotyping protocol with primers Mcc-loxP-F1
(CCCAAACTCATGTGTGTTGTTCC) and Mcc-loxP-R1
(CCTTCCCTTTCTTCCTGTGATTAGC) produced a 182-bp
fragment for the MccD, a 162-bp fragment for MccF, and a
103-bp fragment for Mcc-WT alleles.
In Vivo Proliferation Assay
MccD/D and wild-type siblings (Mcc-WT) were obtained
from heterozygous crossings. Twenty-week-old mice were
injected intraperitoneally with 100 mg/kg BrdU (Sigma-
Aldrich, St. Louis, MO) and killed 2 hours after injection. The
ileum and colon were harvested and fixed in 10% formalin
for immunohistochemistry. Epitope retrieval was performed
in a pressure cooker at 125ºC with DAKO (Glostrup,
Denmark) buffer S2367, pH 9.0 for 2 minutes. The primary
antibody for BrdU (1:50, DAKO) was incubated for 60 mi-
nutes. The number of BrdU-positive cells in each crypt
were counted and divided by the total number of cells in
each crypt to obtain the percentage of BrdU positivity.expression of Irg antimicrobial host defense genes in the
vitro up-regulates the expression of Irga6, Irgb6, and the
with 5–50 mg/mL LPS and harvested for RNA extraction and
ow a representative experiment with 3 replicates. Friedman’s
s used to determine statistical significance. Error bars indicate
A6 staining in the colon of a drug-treated MccF/F mouse. (B)
elium of blood vessels, but no expression in the normal colon.
a of inflammation and erosion of the epithelial layer. (D) Strong
ak focal expression in adenocarcinoma (arrows). (E) Strong
) next to inflammation. No IRGA6 expression in the epithelial
hils and lymphocytes (black arrow). (F and G) Immunohisto-
). (F) Expression in the cytoplasm of isolated plasma cells and
ithelium. (G) Inflammation induced IRGM3 expression in the
a cells and macrophages. All images were taken with a Carl
jectives and Carl Zeiss Axiocam HRc camera (Zeiss, Ober-
100.
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colon region.
Mouse Experimentation and Colon Tissue
Analysis
Sulindac (320 ppm; Sigma-Aldrich) was mixed with
standard chow by Specialty Feeds (Glen Forrest, Western
Australia). Six-week-old mice were given feed containing
sulindac or standard chow and killed after 20 weeks of
sulindac exposure. The number and size of visible lesions in
the proximal colon were determined under a dissecting
microscope. The colon lesions underwent a biopsy exami-
nation (2–13/mouse) together with control specimens
(20–22 mice per group, both males and females).16,18 After
formalin fixation, processing, and sectioning using routine
diagnostic laboratory methods, at least 2 H&E-stained sec-
tions per animal were analyzed by a specialist anatomical
pathologist (J.E.D.) in a blinded fashion. For each biopsy
specimen the features assessed included the following: type
of inflammation (acute and/or chronic) and depth and
severity of inflammation (absent, mild, moderate, or severe).
Mucosal ulceration was regarded as severe acute inflam-
mation and was defined as loss of the colonic mucosa
associated with an acute inflammatory reaction extending at
least through the muscularis mucosae. Mucosal erosion was
regarded as moderate acute inflammation and was defined
as superficial ulceration that involved only the surface
epithelium and superficial underlying lamina propria.
Epithelial dysplasia was graded as negative, indefinite for
low-grade dysplasia, low-grade, or high-grade dysplasia
according to the Riddell classification. Only biopsy speci-
mens that showed neoplastic glands within a desmoplastic
stroma extending beyond the muscularis mucosae were
regarded as invasive cancer (invasive adenocarcinoma).16,18
For E-cadherin and b-catenin protein expression, heat-
induced epitope retrieval of 3-mm tissue sections was per-
formed for 25 seconds in a pressure cooker (total time, 30
min) using a citrate buffer at pH 6.0 (S1699; DAKO). The
primary antibody was biotinylated with anti-mouse Fab
fragment using the DAKO Animal Research Kit. The primary
antibody for E-cadherin (1:500, 610181; BD Biosciences,
Franklin Lakes, NJ) was incubated for 90 minutes, and for
b-catenin (1:500, 610153; BD Biosciences) for 60 minutes.
For AHR expression, heat retrieval of 3-mm tissue sections
was performed for 48 minutes in CC1 buffer, with blocking
for 8 minutes. Sections were stained with 1:50 dilution AHR
antibody (ab84833; Abcam, Cambridge, UK). Ventana’s
OptiView 3,30-diaminobenzidine tetra hydrochloride
Immumohistochemistry Detection Kit was used to amplify
and visualize the signals (Ventana, Roche, Basel,
Switzerland). Omitting the primary antibody was the nega-
tive control and mouse prostate was the positive control.
The slides were counterstained with hematoxylin.
For IRGA6 and IRGM3, heat-induced epitope retrieval of
3-mm tissue sections was performed for 10 minutes at 95ºC
using Tris-EDTA buffer at pH 9.0. Detection of the primary
antibodies, the anti-Irga6 serum (1:8000),63 and anti-Irgm3
(1:100, sc-136317; Santa Cruz, Dallas, TX), was achieved
with the ImmPRESS system (MP-7401; Vector, Burlingame,CA). The horseradish-peroxidase color reaction was per-
formed with the peroxidase substrate kit HistoGreen (E109;
Linaris, WertheimBettingen, Germany). The nuclei were
counterstained with Nuclear Fast Red.
Mouse Transcriptome and Pathway Analysis
A subset of mice (5–8 per group, all males) was killed
after 10 weeks of sulindac exposure and the colon mucosa
was harvested by light scraping and snap-frozen. RNA was
extracted (74104, RNeasy mini kit; Qiagen, Hilden, Germany).
Gene expression profiling was conducted using Mouse
Transcriptome Array 1.0 (Affymetrix) at the Ramaciotti
Centre for Genomics (Sydney, Australia). Quality control was
performed using the Affymetrix Expression Console.
Normalization and probe-set summarization was performed
using the robust multichip average method of the Affymetrix
Power Tools apt-probe set-summarize software (version
1.16.1) (using the -a rma option) resulting in 72,688 tran-
script clusters. Mouse gene symbols were assigned to each
transcript cluster using Affymetrix NetAfx annotations
(version na34.1 mm10). Differential expression between
experimental groups was assessed using limma via the lim-
maGP tool in GenePattern (Broad Institute, San Diego, CA).64
Mouse gene symbols were mapped to human orthologs using
version 78 of the Ensembl database (EMBL-EBI, Hinxton, UK).
The transcript profiling data have been deposited at NCBI
Gene Expression Omnibus (GSE84391–GEO) and is freely
available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token¼kzwlcwasldsrfen&acc¼GSE84391.
Functionally associated gene sets were identified using
GSEA on a ranked list of the limma moderated t statistics,
from each pair-wise comparison, against the 50 Hallmark
gene sets from v5.0 of the MSigDB (Broad Institute).26 The
most significantly down-regulated genes (Q < 0.05) in
recognized DNA repair pathways were further identified
with network analyses of the MccDIEC data (STRING, Cyto-
scape, KEGG) and pathway annotations in GeneCards.
Comparison of Sulindac-Induced Colon
Inflammation and the DSS Colitis Model
Publicly available raw gene expression data from a
previous DSS colitis experiment34 were downloaded from
GEO (accession GSE22307). Robust Multi-array Average
(RMA) values were generated and differential expression
between days 0 and 6 of DSS treatment was determined
using limma65 and compared with the data from this study
(MccF/F). A probe set was considered differentially
expressed in either study if Q < 0.05. The official gene
symbol was used to map between array platforms,
providing a total of 18,898 probe sets. Log fold-change be-
tween the end points and controls were plotted for probe
sets that were differentially expressed in 1 or both of the
studies. Correlations were calculated using the Pearson
correlation coefficient (r).
qPCR Analysis
cDNA was prepared using the Quantitect Reverse Tran-
scription Kit (205311; Qiagen). Gene expression changes in
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from 3–6 mice/group. In vitro validation of Irg gene
expression was conducted using mouse colon cancer cells
CT26.WT (CRL-2638; ATCC, Manassas, VA), which were
treated with 5–50 mg/mL lipopolysaccharide (InvivoGen,
San Diego, CA) for 2–6 hours. Expression of DNA damage
response genes was analyzed in MEFs, treated with 400
mmol/L H2O2 (AJA260; ThermoFisher, Waltham, MA) for
1–6 hours. The qPCR was always conducted in triplicate for
each specimen.
The following TaqMan assays (Life Technologies, Carls-
bad, CA) were used: Mm01262684_m1 (Mcc),
Mm01168399_m1 (Mmp10), Mm00439491_m1 (Mmp13),
Mm00443610_m1 (Axin2), Mm00438889_m1 (Lgr5), and
Mm99999915_g1 (Gapdh).
Universal Probe Library (UPL; Roche Applied Science,
Mannheim, Germany) assay primers and probes were
as follows: Tgtp2_forward (F) (ccagatcaaggtcaccactg),
Tgtp2_reverse (R) (gagatgattttgctttccctttt), UPL probe 78;
Iigp1_3_F (tgtttggagtggatgaaacatct), Iigp1_3_R (cctccacct-
gatccacctc), UPL probe 48; Atm_F (tgcagatttatatccatcatcca-
c),Atm_R (tttcatggattcataagcacctt), UPL probe 106; Rad1_F
(tgtctcctgacaagccctattt), Rad1_R (tgttgacctgggtcttatcaca),
UPL probe 31; Mlh1_F (gttttactccattcggaagca), Mlh1_R
(ggagccaggcatgtcact), UPL probe 25; Msh2_F (gctgggatgt-
gacgaagc), Msh2_R (cagaataattttctcaccttgctct), UPL probe 27;
Msh3_F (ttgaaataaagaactcggctgtatc), Msh3_R (ggctca-
cagcttttgtgctt), UPL probe 33; Cyp2c68_F (acattggccagtgcct-
tact), Cyp2c68_R (ggcttctttcattgcctcat), UPL probe 100; and
Mip2 left (aaaatcatccaaaagatactgaacaa), Mip2 right
(ctttggttcttccgttgagg), UPL probe 26.
Cell Cycle and Protein Analysis
MCC was stably knocked down in HCT116 (CCL-247;
ATCC) colon cancer cells using the Mission short hairpin
RNA Human Gene Family Set (SHCLNG-NM_002387; Sigma-
Aldrich) and a lentiviral transduction method (MCC-KD
cells).11,66 MCC-KD and NT cells were dosed with 10 J/m2
UV radiation (UV-C) using a UV Stratalinker 1800 (Stra-
tagene, La Jolla, CA). MEFs were treated with 400 or 600
mmol/L H2O2 for up to 6 hours or treated with 400 mmol/L
for 2 hours and then allowed to recover in fresh medium.
Cell-cycle distribution was measured by flow cytometric
analysis of propidium iodide–stained, ethanol-fixed cells on
a BD FACS Canto II (BD Biosciences) using Cell Quest (BD
Biosciences) and ModFit (Verity Software, Topsham, ME).
Western blots were probed with antibodies raised to MCC
(610740, BD Biosciences), pChk2-T68, pChk1-Ser345,
pRb807/811 (2661, 2341, 8516; Cell Signaling, Danvers,
MA), Rb (554136; BD Pharmingen, BD Biosciences), and
gH2AX (10856-1-AP; Proteintech, Rosemont, IL).
Comet Assay
The comet assay was performed using the CometAssay
Reagent Kit for Single Cell Gel Electrophoresis Assay
following the manufacturer’s instructions (4250-050-01;
Trevigen, Gaithersburg, MD). Exponentially growing cells
were treated with 10 nmol/L to 1 mmol/L SN38 (SelleckChemicals, Houston, TX) for 2 hours. High-resolution images
of the comets formed were generated using the Leica DM
6000 Power Mosaic microscope (Leica Microsystems, Wet-
zlar, Germany). Tail length was quantified using the Open-
Comet v1.3 ImageJ (National Institutes of Health, Bethesda,
MD) plug-in from comets generated from 3 independent
experiments.
Statistical Analysis
Differences in messenger RNA/protein expression,
epithelial proliferation, number/size of lesions, cell-cycle
phases, and comet tail lengths were compared using
t tests, analysis of variance or the corresponding nonpara-
metric tests, and all frequencies with the Fisher exact test
(GraphPad Prism, San Diego, CA). P < .05 was considered
significant. In bioinformatics analyses the significance was
corrected for multiple comparisons and Q < 0.05 was
considered significant.
All authors had access to the study data and reviewed
and approved the final manuscript.
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